Navigation Links
Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
Date:7/15/2009

MORRISTOWN, N.J., July 15 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida ("Watson"), has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market its trospium chloride extended-release 60 mg capsules prior to the expiration of a patent owned by Supernus Pharmaceuticals, Inc. Watson's trospium chloride extended-release capsules are the generic version of Allergan Inc.'s Sanctura XR((R))( )product, which is indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency.

Allergan filed suit against Watson on July 13, 2009 in the U.S. District Court for the District of Delaware seeking to prevent Watson from commercializing its products prior to expiration of U.S. patent number 7,410,978. Allergan's suit was filed under the provisions of the Hatch Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA for up to 30 months or until final resolution of the matter before the court, whichever occurs sooner.

Watson believes it may be first to file an ANDA for generic trospium extended-release capsules. For the twelve-months ended March 31, 2009, Sanctura XR((R)) had total U.S. sales of approximately $42 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of brand pharmaceuticals focused on Urology, Women's Health and Nephrology/Medical.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Watson's Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the difficulty of predicting the timing or outcome of litigation related to patent infringement; the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

Sanctura XR((R)) is a registered trademark of Allergan, Inc.

(Logo:http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
2. Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
5. Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
6. Watson to Acquire Arrow Group
7. Watson Files FDA Application for Generic Mucinex(R) D
8. Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
9. Watson-Marlow Releases Informative Video Featuring Showcased High Purity Pumps, Tubing and Fillers at Interphex 2009
10. Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
11. Watson Files FDA Applications for Generic Mucinex(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... BROOK, Ill. (PRWEB) , ... December 06, 2016 ... ... disruptions in their brain networks that can be seen on a type of ... disease (PD) is a progressive disorder of the central nervous system characterized by ...
(Date:12/6/2016)... ... December 06, 2016 , ... Men with gum disease are ... serious health problems, such as cardiovascular illness, according to research cited in a ... Periodontics & Dental Implant Center notes that the correlation between periodontal disease and ...
(Date:12/6/2016)... ... ... According to a November 1 article published on Bustle, there ... drinking enough water, which can cause bad breath (known medically as halitosis). Dr. Farzad ... not only helps reduce the possibility of bad breath, but it can provide individuals ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... named Ajdin Camaga as a vice president of sales. , “Ajdin understands that ... “He works hard to understand what each client needs, and is persistent in ...
(Date:12/6/2016)... ... December 06, 2016 , ... Mount Sinai Health System today ... of Neurosurgery, where clinicians can confer and order 3D models for their cases. ... basis with quick turnaround times. This resource will be the first of its ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... Dec. 6, 2016  Nearly 30 million people in ... the epidemic of diabetes. 1 However, nearly 40% ... glucose levels (hyperglycemia) and significant glucose variability. 2 These ... including cardiovascular events. If left untreated, hyperglycemia can lead ... disease or blindness. 3 As part ...
(Date:12/6/2016)... , Dec. 6, 2016 With opioids commonly used for ... the prescription drug market that has led to nationwide fatalities. ... to eight times stronger than heroin or morphine, resulting in likelihood ... , ... , vice president, clinical operations, Behavioral Health for HMC HealthWorks, explained ...
(Date:12/6/2016)...  Blueprint Medicines Corporation (NASDAQ: BPMC ), ... for patients with genomically defined diseases, today announced that ... million in shares of its common stock. In addition, ... option to purchase up to an additional of $18,750,000 ... with the public offering. All shares of common stock ...
Breaking Medicine Technology: